View Older Stories View More Recent Stories
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
How could tariffs shake up the pharma sector?
-
Abbvie (ABBV) PT Raised to $195 at Berenberg
-
BMO Capital Reiterates Outperform Rating on Abbvie (ABBV) as They Enter Obesity
-
BMO Capital Reiterates Outperform Rating on Abbvie (ABBV) as They Enter Obesity
-
Bernstein Reiterates Market Perform on Abbvie (ABBV) Following Gubra Agreement
-
Abbvie (ABBV) PT Raised to $223 at BofA Securities
-
AbbVie (ABBV) appoints CEO as Chairman of board
-
AbbVie (ABBV) Appoints CEO Robert A. Michael as Chairman of the Board of Directors
-
AbbVie (ABBV) Declares $1.64 Quarterly Dividend; 3.4% Yield
-
AbbVie's Allergan Aesthetics set to launch three new training centers in U.S.
-
AbbVie (ABBV) and Xilio Therapeutics (XLO) Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
-
AbbVie (ABBV) Announces FDA Approval of EMBLAVEO
-
Abbvie (ABBV) PT Raised to $215 at BMO Capital as 'Guidance Raise Gives More Confidence'
-
Abbvie (ABBV) PT Raised to $214 at Guggenheim
-
Abbvie (ABBV) PT Raised to $210 at Leerink Partners
-
Abbvie (ABBV) PT Raised to $220 at Raymond James
-
Abbvie (ABBV) PT Raised to $212 at Goldman Sachs
-
AbbVie (ABBV) Tops Q4 EPS by 10c, Offers Guidance
-
AbbVie (ABBV) call put ratio 1.8 calls to 1 put into quarter results
-
AbbVie (ABBV) call put ratio 1.1 calls to 1 put into quarter results
-
Raymond James Reiterates Outperform Rating on Abbvie (ABBV)
-
Abbvie (ABBV) PT Raised to $227 as Piper Sandler 'Likes the Chances for Upside'
-
Abbvie (ABBV) PT Raised to $208 at Goldman Sachs
-
AbbVie (ABBV) Completes Acquisition of Nimble Therapeutics
-
AbbVie (ABBV) and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
-
Abbvie (ABBV) PT Lowered to $212 at Guggenheim
-
BMO Capital Reiterates Outperform Rating on Abbvie (ABBV) as I&I Portfolio Sees New Avenues for Growth in 2025
-
AbbVie (ABBV) Falls 2% with Presentation at JPMorgan Ongoing
-
Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
-
AbCellera (ABCL) Expands Collaboration with AbbVie (ABBV) to Develop Novel T-Cell Engagers for Oncology
-
AbbVie (ABBV) and REGENXBIO (RGNX) Announce Updates on the ABBV-RGX-314 Clinical Program
-
AbbVie (ABBV) to record $3.5B impairment charge related to the emraclidine
-
Abbvie (ABBV) PT Lowered to $211 at Truist Securities; 'We Like Longer-term Outlook for ABBV'
-
TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'
-
AbbVie (ABBV) says Q4 EPS expected to include acquired IPR&D and milestones expense of $1.6 billion
-
Piper Sandler Highlights NBIX, ITCI, ALKS, AXSM as High Conviction Ideas in Biotechnology
-
TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
-
Abbvie (ABBV) PT Raised to $220 at Piper Sandler, Reflecting Estimates Increase for Skyrizi & Rinvoq
-
AbbVie (ABBV) to Acquire Nimble Therapeutics
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
AbbVie (ABBV) Completes Acquisition of Aliada Therapeutics
-
This pharma stock is TD Cowen's Best Idea for 2025
-
TD Cowen Names Abbvie (ABBV) Best Idea for 2025
-
AbbVie (ABBV): Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-
-
AbbVie (ABBV) Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
-
Leerink Partners Upgrades Abbvie (ABBV) to Outperform
-
JPM just added these stocks to its Analyst Focus List - giving one 148% upside
-
AbbVie (ABBV) call put ratio 1 call to 6.4 puts
-
Abbvie (ABBV) PT Lowered to $208 at BMO Capital
